{"id":"gemigliptin-glimepiride-combination","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Nasopharyngitis"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Gastrointestinal disturbances"}]},"_chembl":{"chemblId":"CHEMBL1481","moleculeType":"Small molecule","molecularWeight":"490.63"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is a dual-mechanism combination therapy for type 2 diabetes. Gemigliptin, a DPP-4 inhibitor, prolongs the action of incretin hormones (GLP-1 and GIP) to enhance glucose-dependent insulin secretion. Glimepiride, a meglitinide-class sulfonylurea, directly stimulates insulin release from pancreatic beta cells. Together, they address both incretin-based and direct insulin secretion pathways to lower blood glucose.","oneSentence":"Gemigliptin inhibits dipeptidyl peptidase-4 (DPP-4) to increase incretin levels and insulin secretion, while glimepiride stimulates pancreatic beta cells to release insulin directly.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:13:52.412Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT02609815","phase":"NA","title":"Initial Combination of Gemigliptin and Metformin on Microbiota Change","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2015-11-01","conditions":"Diabetes","enrollment":70},{"nctId":"NCT01890629","phase":"PHASE4","title":"Effects of Gemigliptin Versus Sitagliptin or Glimepiride With Metformin on Glucose Variability(MAGE, Glucose SD) Patients With Type 2 DM(STABLE Study)","status":"COMPLETED","sponsor":"LG Life Sciences","startDate":"2013-05","conditions":"Type 2 Diabetes Mellitus","enrollment":69},{"nctId":"NCT02089126","phase":"PHASE3","title":"Phase III Trial to Evaluate the Efficacy and Safety of Gemigliptin 50mg qd Added to Ongoing Glimepiride as Fix-dose Combination in Patients With Type 2 Diabetes","status":"UNKNOWN","sponsor":"LG Life Sciences","startDate":"2014-06","conditions":"Type 2 Diabetes Mellitus","enrollment":230}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Gemigliptin/Glimepiride combination","genericName":"Gemigliptin/Glimepiride combination","companyName":"LG Life Sciences","companyId":"lg-life-sciences","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Gemigliptin and glimepiride are a combination of medications used to treat type 2 diabetes mellitus. This combination works by blocking the sulfonylurea receptor 1, Kir6.2, which helps to lower blood sugar levels.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}